{"filing":{"accession_number":"0001104659-26-072633","cik":"0000894158","ticker":"TOVX","company_name":"Theriva Biologics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"tm2617564d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926072633/tm2617564d1_8k.htm"},"events":[{"id":5272,"run_id":4623,"accession_number":"0001104659-26-072633","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Theriva Biologics announced publication of Phase 1 clinical trial results for VCN-01 in head and neck squamous cell carcinoma (HNSCC), including median progression-free survival and overall survival data, biomarker findings, and mechanistic insights. These clinical results are material to investor assessment of the company's pipeline and the program's viability.","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6105,"accession_number":"0001104659-26-072633","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of Phase 1 clinical trial results for VCN-01 in HNSCC, including median PFS and OS data, biomarker findings, and mechanistic insights. While clinical trial results are material to a biopharmaceutical company's prospects, this does not fit the standard earnings_release category (which typically covers financial results) nor any other specific event type in the taxonomy. The disclosure is material to investors assessing the company's pipeline and clinical progress, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:11:12.425236+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6107,"accession_number":"0001104659-26-072633","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of Phase 1 clinical trial results for VCN-01 in HNSCC, including median PFS and OS data, biomarker findings, and mechanistic insights. While clinical trial results are material to a biopharmaceutical company's development pipeline and investor assessment, this does not fit the standard taxonomy categories (not an earnings release, not a regulatory approval/milestone event, not a material impairment or litigation). The event is material because it provides substantive clinical efficacy and safety data that would affect investor perception of the program's viability, but the specific event type is best classified as \"other_material\" given the absence of a dedicated clinical-trial-results category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:11:12.425236+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6105,"accession_number":"0001104659-26-072633","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of Phase 1 clinical trial results for VCN-01 in HNSCC, including median PFS and OS data, biomarker findings, and mechanistic insights. While clinical trial results are material to a biopharmaceutical company's prospects, this does not fit the standard earnings_release category (which typically covers financial results) nor any other specific event type in the taxonomy. The disclosure is material to investors assessing the company's pipeline and clinical progress, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:11:12.425236+00:00","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-06-11"},{"id":6107,"accession_number":"0001104659-26-072633","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces publication of Phase 1 clinical trial results for VCN-01 in HNSCC, including median PFS and OS data, biomarker findings, and mechanistic insights. While clinical trial results are material to a biopharmaceutical company's development pipeline and investor assessment, this does not fit the standard taxonomy categories (not an earnings release, not a regulatory approval/milestone event, not a material impairment or litigation). The event is material because it provides substantive clinical efficacy and safety data that would affect investor perception of the program's viability, but the specific event type is best classified as \"other_material\" given the absence of a dedicated clinical-trial-results category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:11:12.425236+00:00","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-06-11"}]}